Galenica AG · SIX:GALE

Galenica — Investor Presentation (August 2019)

46 slides from Galenica's investor presentation, August 2019

  1. Slide 1: Galenica Group Investor Presentation

    Galenica Group Investor Presentation August 2019

  2. Slide 2: Agenda

    Agenda 1 History 3 2 Galenica at a glance 6 3 Business Sectors 11 4 Financial track record 16 5 Business update H1 2019 18 6 Financial results H1 2019 26 7 Market update H1 2019 38 8 Regulatory projects update H1 2019 40 August 2019 © Galenica Group 2

  3. Slide 3: Building the leading Swiss healthcare platform over 90 years

    1 Building the leading Swiss healthcare platform over 90 years Creation of Foundation of Acquisition of Amavita uniform Acquisition of Galenica as a Merfen® and brand in Bahnhof wholesaler Vita-Merfen® Organic and Switzerland Apotheke acquisition-led expansion of Acquisition of Expansion of IPO of p

  4. Slide 4: History of resilient growth and margin improvement

    1 History of resilient growth and margin improvement Logistics, HealthCare Information & Retail1,4 Galenica 2008–18 CAGRs 2008-18 3.4% Retail market sales2 1.9% sales CAGR Galenica net sales 3.4% Galenica EBIT3 14.7% 2008-18 6 14.7% 3’141 3’165 6 6.0% EBIT CAGR3 2’915 3’009 2’661 2’766 2’826 2008-18

  5. Slide 5: April 2017: Outstanding IPO of Galenica Santé

    1 7 April 2017: Outstanding IPO of Galenica Santé  Largest IPO in Europe in H1 2017 and first sizeable 100% subsidiary IPO since years  Multiple oversubscription with pricing at the top end of the price range at CHF 39.00 HF 13% RoW 15% PB  Broadly diversified 30% US 48.75m 12% 48.75m allocation

  6. Slide 6: Galenica is the leading healthcare provider in Switzerland

    2 Galenica is the leading healthcare provider in Switzerland 2018 net sales CHF3’165m 2018 EBIT1 CHF154m Health & Beauty Services Retail Products & Brands Market position2 #1 Consumer Health market position2 #1 Market position2 #1 2018 net sales 2018 EBIT 2018 net sales 2018 EBIT (pre eliminations o

  7. Slide 7: Operating in a stable and attractive Swiss healthcare market

    Operating in a stable and attractive Swiss healthcare market 2 with favourable long-term fundamentals Resilient, stable Swiss healthcare retail sector2 Pharmaceutical market in Switzerland (2018)1 CHF bn (based on ex-manufacturer price) 2018-22 CAGR 1.7%3 By value−CHF6.0bn By volume−187 million pack

  8. Slide 8: Experienced management team with proven track record

    2 Experienced management team with proven track record Jean-Claude Clémençon − CEO since IPO CEO − 30 years industry experience of which 24 years at Galenica Group − Joined Galenica Group in 1995 − Previously, Head of Retail Business Sector, Head of Logistics and HCI at Galenica Group, Head of Manuf

  9. Slide 9: Galenica: The first choice for health, beauty and wellbeing

    2 Our ambition and self-perception Galenica: The first choice for health, beauty and wellbeing. August 2019 © Galenica Group 9

  10. Slide 10: Our Strategy - the power of Leverage

    2 Our Strategy - the power of 3 drives sustained value creation Products & Brands − Leverage leading positions to promote − Develop and launch own and partner higher margin and exclusive products brands and products for pharmacies Leverage − Further expand and optimise retail 2017 2016 Retail networ

  11. Slide 11: The largest pharmacy retailer in Switzerland

    3 The largest pharmacy retailer in Switzerland Retail Network of chains (# of pharmacies as of 30 June 2019) Webshop Competitive positioning—#1 market position4 − Largest branded pharmacy network by By number of pharmacies5 Total # of pharmacies as of 2017 number of pharmacies in Switzerland  1’800

  12. Slide 12: Ongoing pharmacy network consolidation and optimisation

    3 Ongoing pharmacy network consolidation and optimisation Retail  Proven track record of delivering synergies  Widely spread pharmacy network covers every through streamlining of business processes and Region in Switzerland creating value through acquisitions and network optimisation Marketing IT

  13. Slide 13: Diversified product portfolio for health, beauty and wellbeing

    3 Diversified product portfolio for health, beauty and wellbeing Retail GaleniCare’s retail product offering in % of sales1 12% 37% 19% 52% 17% 11% 4% Beauty Nutrition, Personal OTC medicines Prescription medicines and Patient Care of which originals of which generics 1 Sales YTD December 2018, incl

  14. Slide 14: Leading role in Consumer Health with broad and innovative product portfolio

    Leading role in Consumer Health 3 with broad and innovative product portfolio Products & Brands Portfolio Competitive position: #1 Consumer Healthcare1 market position OTC Consumer Health ORAL PAIN & Skincare brands REMEDIES5 Market share2 (%) No. 1 33% market share2 5.7 5.3 5.3 TOPICAL PAIN Exclusi

  15. Slide 15: Leader in pre-wholesale and wholesale distribution

    Leader in pre-wholesale and wholesale distribution, supported 3 by an innovative healthcare information business Services Services Competitive positioning - #1 market position1 − Pre-wholesale outsourced storage and distribution Pre-wholesale market share % Wholesale market share % − Logistics servi

  16. Slide 16: Long-term track record of sustainable growth and attractive cash generation

    Long-term track record of sustainable growth and 4 attractive cash generation … Logistics, HealthCare Information & Retail1,4 Galenica 2008–18 CAGRs Retail market sales2 1.9% Galenica net sales 3.4% Net sales (CHFm) Galenica EBIT3 14.7% 3’009 3’141 7 3’165 7  Above market growth 2’766 2’826 2’915 2

  17. Slide 17: Demonstrating strong performance in both segments

    4 … demonstrating strong performance in both segments Health & Beauty Services Retail Health & Beauty Logistics and HCI Services 17.5% 3.5% 0.8% 2.2% Net sales (CHFm) 2’245 2’329 2’362 1 2’372 1 2’076 2’158 2’171 1’393 1’437 1’479 1 1’525 1 1’246 1’335 557 2008A … 2013A Health 2014A & Beauty 2015A 2

  18. Slide 18: Guidance 2019 slightly increased

    Based on the good 1st HY results: 5 Guidance 2019 slightly increased Increase of − net sales: + 2.2% − EBIT1): + 8.3%  sustainable sales growth above market  strong improvement of profitability  progress in efficiency and synergy projects 1) adjusted: on a comparable basis, excluding the effects

  19. Slide 19: All Business sectors contributed to the good results

    Networked with all healthcare market players 5 All Business sectors contributed to the good results Products Patient / Customer & Brands Industry Retail Services August 2019 © Galenica Group 19

  20. Slide 20: Highlights 1st HY 2019 Retail: Strong expansion activities

    Highlights 1st HY 2019 5 Retail: Strong expansion activities  + 8 additional own pharmacies  network of total 508 POS  new services  more than 40,000 products  Bichsel acquisition  Curarex acquisition August 2019 © Galenica Group 20

  21. Slide 21: Retail: our latest acquisition – The Bichsel Group

    Highlights 1st HY 2019 5 Retail: our latest acquisition – The Bichsel Group Pharmacy store Magistral Prescriptions customised production Manufacture infusions, rinsing solutions Home Care August 2019 © Galenica Group 21

  22. Slide 22: Products & Brands: Expansion of partnerships and portfolio

    Highlights 1st HY 2019 5 Products & Brands: Expansion of partnerships and portfolio  New own derma-cosmetic brand  National advertising campaign  Expansion of partnerships and product portfolio August 2019 © Galenica Group 22

  23. Slide 23: Services: Pleasing progress with key strategic projects

    Highlights 1st HY 2019 5 Services: Pleasing progress with key strategic projects  Introduction new ERP system on track  Modernisation logistic centre on track  New products and services August 2019 © Galenica Group 23

  24. Slide 24: Outlook 2019 Focus on our strategic axes

    Outlook 2019 5 Focus on our 3 strategic axes Expansion − Further strengthening the three B2C channels − New services and products − New partnerships Innovation − Continue the positive momentum of the strategic projects  ERP system Efficiency  logistic centre Lausanne August 2019 © Galenica Group 2

  25. Slide 25: Long-term outlook: From multi-channel to omni-channel

    Long-term outlook 5 From multi-channel to omni-channel … multi-channel omni-channel August 2019 © Galenica Group 25

  26. Slide 26: Galenica Group Sales growth above market

    Galenica Group 6 Sales growth above market Net sales (in million CHF) +2.2% +4.3% +11.1% +1.3% H1 2019 H1 2018 August 2019 © Galenica Group 26

  27. Slide 27: Retail Business sector: Important sales growth driven by expansion

    Retail Business sector 6 Important sales growth driven by expansion Net sales (in million CHF) +4.3% 48.6% Elements of growth: Expansion1: +2.6% +1.3% +5.1% Organic2: +0.5% +1.3% -0.7% thereof impact of price reductions3: -1.6% -1.2% -1.9%  Strong expansion of pharmacy network: 13 pharmacies added,

  28. Slide 28: Products & Brands: Consolidation of leading position in Swiss Consumer Healthcare

    Products & Brands Business sector - Consolidation of leading 6 position in the Swiss Consumer Healthcare market Net sales (in million CHF) +11.1% +3.0% International sales 53.0% Sales in the Swiss Market +13.6%  Distribution of P&G brands Vicks® and Metamucil® and launch of Dermafora® with ~ 10% im

  29. Slide 29: Services Business sector: Gain of market shares in the pharmacy market

    Services Business sector 6 Gain of market shares in the pharmacy market Net sales (in million CHF) +1.3% 49.6% impact of price reductions1: -2.4% -1.9% -2.6%  Pleasing growth of ~ 2.2% in the pharmacy wholesale market (portion ~ 65%) outweighs slight decline of ~ 0.8% in the physician wholesale mar

  30. Slide 30: Results and profitability improved

    Galenica Group 6 Results and profitability improved EBITDA (in million CHF) EBIT (in million CHF) +41.7% +18.1% 4.9% 4.5% 5.2% EBIT Margin (ROS) August 2019 © Galenica Group 30

  31. Slide 31: EBITDA and EBIT adjustments

    Galenica Group 6 EBITDA and EBIT adjustments1 EBITDA (in million CHF) EBIT (in million CHF) H1 H1 H1 H1 2019 2018 2019 2018 EBITDA 126.7 89.4 EBIT 82.8 70.1 Adjustment IAS 19 -0.3 +4.8 Adjustment IAS 19 -0.3 +4.8 Adjustment IFRS 16 -24.6 - Adjustment IFRS 16 -1.4 - EBITDA adjusted 101.8 94.2 EBIT ad

  32. Slide 32: EBIT / EBIT margin adjusted

    Galenica Group 6 Results and profitability improved EBIT / EBIT margin adjusted 1 (in million CHF / %) 5.1% +8.3% 4.8% 7.7% +11.0% 7.3% 1.9% +1.2% 1.9% August 2019 © Galenica Group H1 2019 H1 2018 1 Excluding effects of IAS 19 and IFRS 16, half-year report on pages 20 and 21 32

  33. Slide 33: Stable financial and tax costs

    Galenica Group 6 Stable financial and tax costs Financial result (in million CHF) Tax rate -1.1 -1.3 -1.9 1 -0.1 -1.3 -0.2 -1.5 -2.1 -2.7 2018 H1 2018 H1 2019 Financial result adjusted2 IAS 19 and IFRS 16 effects2  The Swiss Tax Reform has had no material impact on income taxes 1 Effective tax rate

  34. Slide 34: Pleasing net profit evolution

    Galenica Group 6 Pleasing net profit evolution Net profit (in million CHF) +15.0% One-off deferred tax effect Net profit adjusted1, excluding effects of IAS 19 +7.6% and IFRS 16, 2018 w/o one-off tax effect IAS 19 and for H1 2019 IFRS 16 and IAS 19 effects -0.1 1 Details of the adjustments in the ha

  35. Slide 35: Investments in efficiency projects

    Galenica Group 6 Investments in efficiency projects Investments in million CHF % of net sales 1.6% 1.4% 1.5% Cash conversion1 74% 77% 76% Investments in intangible assets Investments in tangible assets 1 Calculated as (EBITDA adjusted-CAPEX)/EBITDA adjusted, EBITDA adjusted excluding effects of IAS

  36. Slide 36: Free cash flow impacted by working capital, investments and acquisitions

    Galenica Group - Free cash flow impacted by working capital, 6 investments and acquisitions1 in million CHF H1 H1 2019 2018 Cash flow from operating activities 116.0 87.0 before working capital changes Payment of lease liabilities -23.4 - Cash flow from operating activities before 92.6 87.0 working

  37. Slide 37: Strong balance sheet

    Galenica Group 6 Strong balance sheet Net debt / Equity in million CHF Debt coverage 1 2.0x 2.0x 2.6x Debt coverage adjusted 2 1.5x 1.9x 2.0x 50%3 41%3 46%3 30%3 54%4 50%4 48%4 Net debt adjusted5 19%3 16%3 IFRS 16 effect on net debt Equity adjusted5 21%4 16%4 19%4 IAS 19 and IFRS 16 effect on equity

  38. Slide 38: Swiss pharmaceutical market by channel YTD June 2019

    Swiss pharmaceutical market by channel YTD June 2019 7 Modest growth marked by price reductions Value (ex-factory): CHF 2,984.9 million Volume (packs): CHF 93,2 million (CHF +26,8 million / +0.9%) (CHF -0.9 million / -0.9%) Hospitals Hospitals 753.6 million 8.3 million 8.9% +4.2% -4.3% 3.4% 25.3% Dr

  39. Slide 39: Consumer healthcare market in the specialist trade YTD June 2019

    Consumer healthcare market in the specialist trade YTD June 2019 7 Stable market development 3.3% OTC 11.9% +0.5% Personal 1’256 care +0.7% million 22.5% (+0.1%) Patient non-medication 62.2% care -2.7% products -0.4% Nutrition -0.8% Source: PharmaTrend for pharmacies and drugstores in Switzerland, s

  40. Slide 40: Regulatory update: Positive signal from authorities

    Regulatory update 8 Positive signal from authorities Reduction in drug 2018   prices 2019 2020 Decision by the Federal Council Category change of  OTC products1) 2019 Distribution margin LOA IV  LOA V LOA IV extended to the end of 2021 Generics prices Amendment of Health from 2021 … Insurance Ac

  41. Slide 41: Price reductions 2017, 2018 and outlook 2019

    Price reductions 2017, 2018 and outlook 2019 8 Annual savings per channel at public price and ex-factory in million CHF 2017 2018 Outlook 2019 Introduced in H1 2018 Introduced on 1.12.2018 Introduction planned for 1.12.2019 225 Hosp. 44.6 185 Hosp. 41.0 ~142 Physicians 64.8 122 Hosp. Physicians Hosp

  42. Slide 42: Reclassification of OTC's

    8 Reclassification of OTC’s Category A Category B Category C Category D Category E prescription without prescription pharmacy only pharmacy & drugstore sale in all shops repetition with a prescription with a prescription without prescription without prescription without prescribtion ~15% ~85% ~85% ~

  43. Slide 43: Category change of OTC products

    Category change of OTC products 8 Strengthening of the specialist retail trade  Less than 10% of products will leave the specialist retail trade! DE CHF 13 million List D CHF 575 million CB CHF 30 million CD CHF 142 million Source: IQVIA, ex-factory, MAT 10/2018 August 2019 © Galenica Group 43

  44. Slide 44: Swiss Pharmaceutical market – composition of drug prices

    8 Swiss Pharmaceutical market – composition of drug prices Fixed margin elements help to offset price reductions Composition of the price of a prescription/ reimbursable drug: c.3/4 of the retail margin secured by fixed elements ~ 8 %(1) LOA – Retail ~ 8% Per prescription / line service fees FOPH de

  45. Slide 45: Disclaimer

    Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a n

  46. Slide 46: Contact information Investor Relations Media

    Galenica Group - Contact information Investor Relations Media Felix Burkhard Christina Hertig CFO Galenica Head Corporate Communication Tel.: +41 58 852 85 29 Tel.: +41 58 852 85 17 Mail: [email protected] Mail: [email protected] August 2019 © Galenica Group 46

Galenica Group — Investor Presentation (August 2019) on 6ix